Midazolam – first step taken

Karessa has now completed the first step in the development of Midazolam, Karessa.

Now there is a stable product to continue with in the next preclinical phase, which is expected to be completed in the first half of 2019. 

The market for Midazolam in various indication areas is very large. Karessa looks brightly at the possibility of improving the situation for many patients and meeting medical needs that can also provide commercially important successes.

For more information, please contact: 
Mats Nilsson, VD Karessa Pharma Holding AB (publ) 
Tel: +46-8-768 22 33

About Karessa Pharma Holding AB 
Karessa is a Swedish pharmaceutical company with the goal of developing products based on a patented drug delivery platform with direct absorption of active substances from the oral cavity to the bloodstream. For more information, visit karessa.se. Certified Advisor: FNCA Sweden AB, info@fnca.se, +46-8-528 00 399.